Several other brokerages have also recently commented on SNY. Zacks Investment Research cut shares of Sanofi from a hold rating to a strong sell rating in a research note on Friday, October 6th. JPMorgan Chase & Co. restated a neutral rating on shares of Sanofi in a research note on Friday, September 15th. Morgan Stanley cut shares of Sanofi from an overweight rating to an underweight rating in a research note on Friday, December 1st. Barclays raised shares of Sanofi from an underweight rating to an equal weight rating in a report on Wednesday, November 15th. Finally, Bank of America lowered shares of Sanofi from a buy rating to a neutral rating in a report on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the stock. Sanofi currently has an average rating of Hold and a consensus target price of $51.50.
Shares of Sanofi (NYSE SNY) traded up $0.70 during midday trading on Tuesday, reaching $43.90. 1,160,000 shares of the company’s stock traded hands, compared to its average volume of 1,070,233. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.16 and a current ratio of 1.59. Sanofi has a twelve month low of $39.42 and a twelve month high of $50.65. The firm has a market cap of $111,270.00, a PE ratio of 20.14, a price-to-earnings-growth ratio of 2.50 and a beta of 0.86.
ILLEGAL ACTIVITY WARNING: “Nord/LB Reaffirms Neutral Rating for Sanofi (SNY)” was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3127030/nordlb-reaffirms-neutral-rating-for-sanofi-sny.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.